Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC
Nov 4, 2024 · The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan (Dato-DXd) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC). 1 TROPION-Lung10 (NCT06357533) is investigating Dato-DXd plus rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, or rilvegostomig alone vs pembrolizumab (Keytruda) in ...
Positive Trials Continue to Shape the SCLC Treatment Landscape
Nov 8, 2024 · Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD.
GD2-CAR T Induces Tumor Regression in H3K27M-Mutant Diffuse …
Nov 25, 2024 · A phase 1 clinical trial (NCT05316155) investigating the use of GD2-targeted chimeric antigen receptor (CAR) T cells for the treatment of H3K27M-mutant diffuse midline gliomas (DMGs) yielded promising results, demonstrating the feasibility, safety, and early efficacy of this approach. 1. The trial enrolled 13 patients, with 11 receiving GD2-CAR T-cell therapy.
Lenalidomide Break Possible? Study Shows Hope for MRD …
Oct 7, 2024 · Minimal residual disease (MRD) negativity was maintained for at least 1 year after stopping lenalidomide (Revlimid) maintenance in patients with multiple myeloma, according to findings from an observational trial (NCT04221178) presented at the 21st International Myeloma Society Annual Meeting. 1. Findings showed that among evaluable patients (n = 39), the MRD-negativity rate at 12 months ...
Antibody-Drug Conjugates Show Unique Advantage in Breast …
Nov 19, 2024 · Erika P. Hamilton, MD, director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, discusses antibody-drug conjugates (ADCs) in multiple types of breast cancer, and when to use these drugs in sequence.
FDA Approves Perioperative Nivolumab in Resectable NSCLC
Oct 3, 2024 · The FDA approved nivolumab (Opdivo) plus chemotherapy for operable non–small cell lung cancer (NSCLC) treatment. Data from the CheckMate 77T trial (NCT04025879) supports this approval.
Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian …
Sep 15, 2024 · The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 (NCT05489211) study presented at the 2024 ESMO Congress. 1
Improving Outcomes Using Ribociclib in High-Risk Node-Negative …
Nov 21, 2024 · The combination of ribociclib (Kisqali) and a nonsteroidal aromatase inhibitor (NSAI) offers significant benefits for patients with high-risk, node-negative, early-stage breast cancer, according to an analysis of the phase 3 NATALEE trial (NCT03701334). 1 NATALEE enrolled patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, targeting those with stage II and III disease.